[go: up one dir, main page]

PE20141397A1 - Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a - Google Patents

Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a

Info

Publication number
PE20141397A1
PE20141397A1 PE2014000394A PE2014000394A PE20141397A1 PE 20141397 A1 PE20141397 A1 PE 20141397A1 PE 2014000394 A PE2014000394 A PE 2014000394A PE 2014000394 A PE2014000394 A PE 2014000394A PE 20141397 A1 PE20141397 A1 PE 20141397A1
Authority
PE
Peru
Prior art keywords
triaza
oxa
benzo
blueens
cyclohexil
Prior art date
Application number
PE2014000394A
Other languages
English (en)
Inventor
Cosimo Dolente
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141397A1 publication Critical patent/PE20141397A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXI-CICLOHEXIL-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENOS DE FORMULA (I) DONDE R1 ES HALOGENO; R2 ES HETEROARILO, ARILO, CICLOALQUILO(C3-C7), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON OH, HALOGENO, CN, ALCOXI(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 8-CLORO-1-(4-ISOPROPOXI-CICLOHEXIL)-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENO; 1-(4-SEC-BUTOXI-CICLOHEXIL)-8-CLORO-4H,6H-5-OXA-2,3,10b-TRIAZA-BENZO[e]AZULENO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE VASOPRESINA V1a SIENDO UTILES EN EL TRATAMIENTO DE DISMENORREA, HIPERTENSION, SINDROME NEFROTICO
PE2014000394A 2011-09-26 2012-09-24 Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a PE20141397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11182796 2011-09-26

Publications (1)

Publication Number Publication Date
PE20141397A1 true PE20141397A1 (es) 2014-10-13

Family

ID=46881068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000394A PE20141397A1 (es) 2011-09-26 2012-09-24 Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas de la v1a

Country Status (23)

Country Link
US (1) US8828989B2 (es)
EP (1) EP2760871B1 (es)
JP (1) JP5909554B2 (es)
KR (1) KR101682777B1 (es)
CN (1) CN103827121B (es)
AR (1) AR087999A1 (es)
AU (1) AU2012314593B2 (es)
BR (1) BR112014006945A2 (es)
CA (1) CA2844581A1 (es)
CL (1) CL2014000717A1 (es)
CO (1) CO6870036A2 (es)
CR (1) CR20140092A (es)
EA (1) EA024990B1 (es)
EC (1) ECSP14013271A (es)
IN (1) IN2014CN02169A (es)
MA (1) MA35535B1 (es)
MX (1) MX2014003643A (es)
PE (1) PE20141397A1 (es)
PH (1) PH12014500582A1 (es)
SG (1) SG2014010607A (es)
TW (1) TWI553013B (es)
UA (1) UA111623C2 (es)
WO (1) WO2013045373A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4185570B1 (en) * 2020-07-23 2024-10-09 F. Hoffmann-La Roche AG Cyclohexyl substituted triazoles as vasopressin receptor v1a antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1147115E (pt) 1999-01-19 2004-02-27 Ortho Mcneil Pharm Inc Benzodiazepinas triciclicas como antagonistas do receptor da vasopressina
US6765004B1 (en) 1999-06-17 2004-07-20 Ortho-Mcneil Pharmaceutical, Inc. Indoloazepines as vasopressin receptor antagonists
US7119088B2 (en) 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
MX2007002248A (es) * 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
PE20110590A1 (es) * 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
MY150837A (en) * 2008-11-28 2014-02-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Also Published As

Publication number Publication date
EA201490558A1 (ru) 2014-06-30
CL2014000717A1 (es) 2014-10-03
CR20140092A (es) 2014-03-20
EA024990B1 (ru) 2016-11-30
IN2014CN02169A (es) 2015-05-29
AR087999A1 (es) 2014-04-30
ECSP14013271A (es) 2014-05-31
MA35535B1 (fr) 2014-10-02
CA2844581A1 (en) 2013-04-04
CN103827121A (zh) 2014-05-28
AU2012314593B2 (en) 2016-09-29
TW201315737A (zh) 2013-04-16
US20130079333A1 (en) 2013-03-28
WO2013045373A1 (en) 2013-04-04
JP5909554B2 (ja) 2016-04-26
KR101682777B1 (ko) 2016-12-05
AU2012314593A1 (en) 2014-02-20
EP2760871A1 (en) 2014-08-06
MX2014003643A (es) 2014-04-30
CO6870036A2 (es) 2014-02-20
AU2012314593A8 (en) 2014-03-27
UA111623C2 (uk) 2016-05-25
KR20140079790A (ko) 2014-06-27
EP2760871B1 (en) 2018-07-18
US8828989B2 (en) 2014-09-09
TWI553013B (zh) 2016-10-11
PH12014500582A1 (en) 2014-04-28
CN103827121B (zh) 2016-08-03
SG2014010607A (en) 2014-05-29
NZ620653A (en) 2016-03-31
JP2014527993A (ja) 2014-10-23
BR112014006945A2 (pt) 2017-04-04

Similar Documents

Publication Publication Date Title
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
MY175272A (en) Novel benzimidazole derivatives as ep4 antagonists
CL2013002902A1 (es) Compuestos del acido propanoico derivados dek 3-(acetil-amino-fenil)-fenil; procedimiento de preparacion de los compuestos; composicion farmaceutica; y uso como activadores de la forma libre de hemo de la guanilato ciclasa soluble, en el tratamiento de insuficiencia cardiaca, angina de pecho, hipertension, afecciones tromboembolicas, isquemias, entre otras.
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
CO6771441A2 (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
UY32574A (es) Antagonistas del receptor cxcr3
EA201390010A1 (ru) Замещенные триазолопиридины
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201290229A1 (ru) Производные спиролактама и их применение
MX2013001965A (es) Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1
PE20160842A1 (es) Piperidiniltetrahidroquinolinas sustituidas
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
PE20120500A1 (es) Piperidinas sustituidas con heteroilamino y aroilamino como inhibidores de glyt-1
UY32226A (es) Derivados de (dihidro)naftiridinona como antagonistas del receptor de histamina h3
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.

Legal Events

Date Code Title Description
FC Refusal